Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

The macroeconomic consequences of renouncing to universal access to antiretroviral treatment for HIV in Africa: a micro-simulation model.

Ventelou B, Arrighi Y, Greener R, Lamontagne E, Carrieri P, Moatti JP.

PLoS One. 2012;7(4):e34101. doi: 10.1371/journal.pone.0034101. Epub 2012 Apr 13.

PMID:
22514619
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Ouattara EN, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA.

AIDS. 2012 Mar 13;26(5):625-34. doi: 10.1097/QAD.0b013e328350fbfb.

PMID:
22398569
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, Jones L, Smyth C, Kutch KA, Ying-Ru L, Vitoria M, Souteyrand Y, Crowley S, Korenromp EL, Williams BG.

PLoS One. 2012;7(2):e30216. doi: 10.1371/journal.pone.0030216. Epub 2012 Feb 13.

PMID:
22348000
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.

Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; ANRS 12222 Morbidity/Mortality Study Group.

Clin Infect Dis. 2012 Mar 1;54(5):714-23. doi: 10.1093/cid/cir898. Epub 2012 Feb 4.

PMID:
22173233
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.

Bélec L, Bonn JP.

Future Microbiol. 2011 Nov;6(11):1251-60. doi: 10.2217/fmb.11.121. Review.

PMID:
22082287
[PubMed - indexed for MEDLINE]
6.

A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects.

Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ.

BMC Infect Dis. 2011 Sep 17;11:244. doi: 10.1186/1471-2334-11-244.

PMID:
21923929
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.

Ford N, Calmy A, Mofenson L.

AIDS. 2011 Nov 28;25(18):2301-4. doi: 10.1097/QAD.0b013e32834cdb71. Review.

PMID:
21918421
[PubMed - indexed for MEDLINE]
8.

Building a durable response to HIV/AIDS: implications for health systems.

Atun R, Bataringaya J.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S91-5. doi: 10.1097/QAI.0b013e3182218441.

PMID:
21857305
[PubMed - indexed for MEDLINE]
9.

Prevention of HIV-1 infection with early antiretroviral therapy.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team.

N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.

PMID:
21767103
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.

Nash D, Wu Y, Elul B, Hoos D, El Sadr W; International Center for AIDS Care and Treatment Programs.

AIDS. 2011 Jul 31;25(12):1523-33. doi: 10.1097/QAD.0b013e32834811b2.

PMID:
21750418
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.

Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31. doi: 10.1097/QAI.0b013e318227fc34.

PMID:
21694603
[PubMed - indexed for MEDLINE]
12.

Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.

Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, Maxwell N, Maskew M, Prozesky H, Fox MP, Westfall A, Egger M; IeDEA Southern Africa Collaboration.

AIDS. 2011 Sep 10;25(14):1761-9. doi: 10.1097/QAD.0b013e328349822f.

PMID:
21681057
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.

Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, Maotoe T, Fox M.

AIDS. 2011 Aug 24;25(13):1603-9. doi: 10.1097/QAD.0b013e32834957da.

PMID:
21646902
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W.

AIDS Res Treat. 2011;2011:769627. doi: 10.1155/2011/769627. Epub 2010 Dec 2.

PMID:
21490784
[PubMed]
Free PMC Article
15.

Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries.

Renaud-Théry F, Avila-Figueroa C, Stover J, Thierry S, Vitoria M, Habiyambere V, Souteyrand Y.

AIDS Res Treat. 2011;2011:749041. doi: 10.1155/2011/749041. Epub 2011 Mar 24.

PMID:
21490783
[PubMed]
Free PMC Article
16.

Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy.

Stover J, Bollinger L, Avila C.

AIDS Res Treat. 2011;2011:738271. doi: 10.1155/2011/738271. Epub 2010 Nov 29.

PMID:
21490782
[PubMed]
Free PMC Article
17.

High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia.

Ferradini L, Ouk V, Segeral O, Nouhin J, Dulioust A, Hak C, Fournier I, Lerolle N, Ngin S, Mean CV, Delfraissy JF, Nerrienet E.

J Int AIDS Soc. 2011 Mar 26;14:14. doi: 10.1186/1758-2652-14-14.

PMID:
21439074
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho.

Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, Triviño L, Makakole L, Ford N.

PLoS One. 2011 Mar 2;6(3):e17609. doi: 10.1371/journal.pone.0017609.

PMID:
21407815
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique.

Lambdin BH, Micek MA, Koepsell TD, Hughes JP, Sherr K, Pfeiffer J, Karagianis M, Lara J, Gloyd SS, Stergachis A.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e33-9. doi: 10.1097/QAI.0b013e3182167e90.

PMID:
21372723
[PubMed - indexed for MEDLINE]
20.

Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand.

Win MM, Maek-A-Nantawat W, Phonrat B, Kiertiburanakul S, Sungkanuparph S.

J Int Assoc Physicians AIDS Care (Chic). 2011 Jan-Feb;10(1):57-63. doi: 10.1177/1545109710387301.

PMID:
21368017
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk